Aura Biosciences, Inc. Temporary Equity, Accretion to Redemption Value, Adjustment
Aura Biosciences, Inc. (AURA) reported Temporary Equity, Accretion to Redemption Value, Adjustment of $10.94 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-23.
Discontinued › Expense Statement › Operating Expenses
us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment · last filed 2022-03-23
- Aura Biosciences, Inc. temporary equity, accretion to redemption value, adjustment for the quarter ending 2021-12-31 was $1.31M, a 38.09% decline year-over-year.
- Aura Biosciences, Inc. temporary equity, accretion to redemption value, adjustment for the quarter ending 2021-09-30 was $3.67M, a 88.30% increase year-over-year.
- Aura Biosciences, Inc. temporary equity, accretion to redemption value, adjustment for the quarter ending 2020-12-31 was $2.12M.
- Aura Biosciences, Inc. temporary equity, accretion to redemption value, adjustment for the quarter ending 2020-09-30 was $1.95M.
- Aura Biosciences, Inc. temporary equity, accretion to redemption value, adjustment for fiscal 2021 was $10.94M, a 38.05% increase from fiscal 2020.
- Aura Biosciences, Inc. temporary equity, accretion to redemption value, adjustment for fiscal 2020 was $7.93M.
| Period end | Temporary Equity, Accretion to Redemption Value, Adjustment 3 month | Temporary Equity, Accretion to Redemption Value, Adjustment 6 month | Temporary Equity, Accretion to Redemption Value, Adjustment 9 month | Temporary Equity, Accretion to Redemption Value, Adjustment 12 month |
|---|---|---|---|---|
| 2021-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $4.98M derived: sum of 2 quarters · filed 2022-03-23 | $10.94M 10-K · filed 2022-03-23 | |
| 2021-09-30 | $3.67M 10-Q · filed 2021-11-24 | $9.63M 10-Q · filed 2021-11-24 | ||
| 2020-12-31 | $2.12M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $4.07M derived: sum of 2 quarters · filed 2022-03-23 | $7.93M 10-K · filed 2022-03-23 | |
| 2020-09-30 | $1.95M 10-Q · filed 2021-11-24 | $5.80M 10-Q · filed 2021-11-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |